Menu
← Oncology Approval Tracker
FDA DECISION ·
Lynozyfic
linvoseltamab-gcpt · Regeneron Pharmaceuticals
Open LinkedIn brief ↓1 min read · estimated
APPROVED USE
What FDA approved
For adults with relapsed or refractory multiple myeloma after at least four prior lines, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
LAMPGEN ANALYSIS
Why it matters
The BCMA×CD3 bispecific antibody expands late-line treatment options, with clinical benefit to be confirmed.
What research teams should watch
Verify required prior drug classes and plan inpatient observation for step-up doses under the labeled risk-management program.
PRIMARY RECORDS